Association of Endocrinologists on Clinical Care Team With Sodium-Glucose Cotransporter 2 Inhibitor Prescription for People With Type 2 Diabetes After Coronary Artery Bypass Grafting: A Two-Center Study.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are underutilized in people with type 2 diabetes after coronary artery bypass grafting (CABG). This study investigated the association of the presence of an endocrinologist on treatment teams with SGLT2 inhibitor prescription in patients with type 2 diabetes after CABG. The presence of an endocrinologist was associated with a more than twofold increase in the odds of obtaining an SGLT2 inhibitor prescription. This finding suggests that involving endocrinologists in these patients' postoperative care may improve prescription and use of SGLT2 inhibitors after CABG.